A randomized trial conducted across the Mass General Brigham health care system has found that the existing echocardiogram data, combined with notification from the trained non-physician coordinators, significantly increased the detection and management of hypertension in patients with left ventricular hypertrophy (LVH). The findings were published in the JAMA Cardiology.

The NOTIFY-LVH study had 648 patients between March 2023 and June 2024. Patients had LVH detected on an echocardiogram, no history of cardiomyopathy, and were not on antihypertensive medications at baseline.

Patients were randomized to either a usual-care control group or an intervention in which population health coordinators notified their clinicians of the LVH finding and offered assistance with follow-up care, including 24-hour ambulatory blood pressure monitoring or cardiology referrals.

After 12 months, 16.3% of patients in the intervention group were prescribed an antihypertensive medication compared with just 5.0% in the control group (adjusted OR: 3.76; 95% CI: 2.09–6.75; P < .001). Hypertension diagnoses were also more frequent in the intervention arm (adjusted OR: 4.43; 95% CI: 2.36–8.33; P < .001), while cardiomyopathy diagnosis rates did not differ significantly between groups.